Topics

ESMO 2019 Showcases Biosimilar Equivalency Data

12:19 EDT 11 Oct 2019 | OncLive

Findings 2019 ESMO Congress showcased that biosimilars for pegfilgrastim, filgrastim, bevacizumab, and trastuzumab demonstrated efficacy and safety equivalency with their reference counterparts in a number of malignancies.

Original Article: ESMO 2019 Showcases Biosimilar Equivalency Data

NEXT ARTICLE

More From BioPortfolio on "ESMO 2019 Showcases Biosimilar Equivalency Data"

Quick Search

Relevant Topic

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...